Background: The taxanes are an important class of agents for the treatment of a broad range
of malignancies including breast cancer. They improve survival in patients with early stage and
metastatic breast cancer. Transducin-like enhancer of split 3 (TLE3) is a transcriptional repressor
which influences growth and microtubule stability and its expression has been implicated in
response to taxane therapy in breast cancer. We investigated the tumor expression of TLE3 in
breast cancer patients, including a large cohort of the triple negative subtype.